republic-os/legislation/us/states/de/152/sb-189.md

type, title, description, jurisdiction, legislature, session, identifier, citation, classification, subjects, status, primary_sponsors, version_count, action_count, vote_count, first_action, last_action, source, source_identifier, source_url, source_hash, vintage, source_snapshot, retrieved_at, confidence, tags

type	title	description	jurisdiction	legislature	session	identifier	citation	classification	subjects	status	primary_sponsors	version_count	action_count	vote_count	first_action	last_action	source	source_identifier	source_url	source_hash	vintage	source_snapshot	retrieved_at	confidence	tags
Bill	AN ACT TO AMEND TITLE 16 OF THE DELAWARE CODE RELATING TO THE UNIFORM CONTROLLED SUBSTANCES ACT AND DRUG TESTING STRIPS.	This Act adds xylazine and it isomers, esters, ethers, salts and salts of isomers, esters and ethers to Schedule III of the Delaware Uniform Controlled Substances Act and expands the authorization for the distribution of testing strips to determine the presence of controlled substances. According to the United States Drug Enforcement Administration, the emergence of xylazine across the United States appears to be following the same path as fentanyl, starting in the Northeast and then spreading to the South and working its way into drug markets westward, and the low cost of xylazine contributes to xylazine’s increased presence in the nation’s illegal drug supply. Xylazine is approved only for veterinary use, xylazine is a non-opioid with increasing presence as an adulterant, often in conjunction with opioids, in the illicit drug supply. When used alone and in conjunction with other drugs, xylazine is implicated as a cause or contributing cause of death in the United States. When used in conjunction with an opioid, such as heroin or fentanyl, xylazine may worsen respiratory depression in the event of a drug overdose, and because xylazine is not an opioid, naloxone is not known to be effective at reversing overdoses, and there is no known antidote or reversal agent for xylazine overdose in humans. This Act also exempts testing strips from the drug paraphernalia statute and expands the limitations on liability for lay individuals and organizations that provide a drug testing strip to an individual who uses drugs to reduce the likelihood of the individual experiencing harm.	us/states/de	Delaware General Assembly	152	SB 189	Delaware SB 189 (152)	bill		enacted	Brian Pettyjohn Bryan Townsend Bryant L. Richardson Laura V. Sturgeon Nicole Poore Russell Huxtable Spiros Mantzavinos Trey Paradee	2	9	2	2023-06-16	2023-08-17	openstates	ocd-bill/6cde1f08-03c3-473d-947b-b00a69e9bacc	https://legis.delaware.gov/BillDetail?LegislationId=140658	89470048b09ad46d989986310dad6bf59cd2c6aae0f58387a5444e8b06f0f835	2026-07-01	https://data.openstates.org/daily/2026-07-01/public.pgdump	2026-07-06	reported	legislation bill us-de

Delaware SB 189 (152) — AN ACT TO AMEND TITLE 16 OF THE DELAWARE CODE RELATING TO THE UNIFORM CONTROLLED SUBSTANCES ACT AND DRUG TESTING STRIPS.

This Act adds xylazine and it isomers, esters, ethers, salts and salts of isomers, esters and ethers to Schedule III of the Delaware Uniform Controlled Substances Act and expands the authorization for the distribution of testing strips to determine the presence of controlled substances. According to the United States Drug Enforcement Administration, the emergence of xylazine across the United States appears to be following the same path as fentanyl, starting in the Northeast and then spreading to the South and working its way into drug markets westward, and the low cost of xylazine contributes to xylazine’s increased presence in the nation’s illegal drug supply. Xylazine is approved only for veterinary use, xylazine is a non-opioid with increasing presence as an adulterant, often in conjunction with opioids, in the illicit drug supply. When used alone and in conjunction with other drugs, xylazine is implicated as a cause or contributing cause of death in the United States. When used in conjunction with an opioid, such as heroin or fentanyl, xylazine may worsen respiratory depression in the event of a drug overdose, and because xylazine is not an opioid, naloxone is not known to be effective at reversing overdoses, and there is no known antidote or reversal agent for xylazine overdose in humans. This Act also exempts testing strips from the drug paraphernalia statute and expands the limitations on liability for lay individuals and organizations that provide a drug testing strip to an individual who uses drugs to reduce the likelihood of the individual experiencing harm.

Version chain

The bill's text revisions, in order — the diff chain from filing to enrollment.

1. Bill Text (committee substitute) — source
2. SA 1 to SB 189 (committee substitute) — source

Votes

• SM — 20–0 (pass) · upper
• SM — 41–0 (pass) · lower

Sponsors

• Brian Pettyjohn — primary (person)
• Bryan Townsend — primary (person)
• Bryant L. Richardson — primary (person)
• Laura V. Sturgeon — primary (person)
• Nicole Poore — primary (person)
• Russell Huxtable — primary (person)
• Spiros Mantzavinos — primary (person)
• Trey Paradee — primary (person)

Timeline

The legislative action history — every referral, reading, and vote.

• 2023-06-16 Introduced and Assigned to Health & Social Services Committee in Senate introduction, referral-committee
• 2023-06-21 Reported Out of Committee (Health & Social Services) in Senate with 4 On Its Merits committee-passage
• 2023-06-22 Amendment SA 1 to SB 189 - Introduced and Placed With Bill amendment-introduction
• 2023-06-22 Amendment SA 1 to SB 189 - Passed By Senate. Votes: 20 YES 1 ABSENT amendment-passage
• 2023-06-22 Passed By Senate. Votes: 20 YES 1 ABSENT passage
• 2023-06-23 Assigned to Administration Committee in House introduction, referral-committee
• 2023-06-29 Reported Out of Committee (Administration) in House with 3 On Its Merits committee-passage
• 2023-06-30 Passed By House. Votes: 41 YES passage
• 2023-08-17 Signed by Governor executive-signature

Source

OpenStates / OpenCivicData bulk snapshot 2026-07-01; origin ocd-bill/6cde1f08-03c3-473d-947b-b00a69e9bacc. Confidence: reported (aggregated from official Delaware legislature records).